Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

PROSTATE CANCER

Final SPARTAN data show OS benefit

Nature Reviews Urology volume 17, page 602 (2020)Cite this article

Subjects

Access through your institution
Buy or subscribe

Mature data from the SPARTAN study, which evaluated the outcomes of apalutamide treatment versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and a PSA doubling time of ≤10 months, have shown a significant overall survival (OS) benefit in this patient group.

Primary analysis results from SPARTAN have previously been published and showed that apalutamide improved median metastasis-free survival (MFS) by 2 years over placebo plus androgen deprivation therapy (ADT). These interim data led to the approval of apalutamide for the treatment of nmCRPC and metastatic castration-sensitive prostate cancer; however, the OS data were immature, although interim analysis of progression-free survival data did suggest an improvement with apalutamide therapy. The prespecified, event-driven final analysis data for SPARTAN have now been reported in European Urology.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Related article

  • Schmid, S. & Omlin, A. Progress in therapy across the spectrum of advanced prostate cancer. Nat. Rev. Urol. 17, 71–72 (2020)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Urology http://www.nature.com/nrurol/

    Annette Fenner

Authors
  1. Annette Fenner
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Annette Fenner.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fenner, A. Final SPARTAN data show OS benefit. Nat Rev Urol 17, 602 (2020). https://doi.org/10.1038/s41585-020-00381-w

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41585-020-00381-w

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer